AstraZeneca is a global biopharmaceutical company that discovers, develops, manufactures, and sells prescription medicines across four therapy areas: Oncology, Cardiovascular/Renal/Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Disease. Oncology is the largest and fastest-growing franchise, built around key products including Tagrisso (EGFR-mutated lung cancer), Imfinzi (immunotherapy across multiple cancers), Calquence (blood cancers), Lynparza (PARP inhibitor), and Enhertu (an antibody-drug conjugate co-developed with Daiichi Sankyo). CVRM is led by Farxiga, an SGLT2 inhibitor approved across diabetes, heart failure, and chronic kidney disease, though Farxiga faces U.S. patent expiry in April 2026. R&I is anchored by biologics for severe asthma, including Fasenra and Tezspire. Rare Disease is operated through the Alexion unit, centered on complement inhibitors Ultomiris and Soliris for rare blood and neurological disorders. AstraZeneca sells primarily through hospital and specialty pharmacy channels. The business model relies on patent-protected pricing during exclusivity periods, broad indication expansion for each medicine, and a growing stream of alliance revenue from co-commercialization partnerships. Core gross margins run around 82%, with R&D reinvestment at roughly 23% of revenue. Geographically, the U.S. accounts for roughly 42% of product sales, with emerging markets — including a large China business — contributing about 27%. AstraZeneca targets $80B in total revenue by 2030, driven by new product launches, indication expansions, and investments in next-generation modalities including ADCs, bispecific antibodies, and CAR-T.